Alto Neuroscience is a clinical-stage biopharmaceutical company developing drugs for psychiatric and neurological disorders, with no approved products and no revenue. Alto's pipeline spans seven programs targeting major depressive disorder (MDD), treatment-resistant depression (TRD), bipolar depression, schizophrenia (specifically cognitive symptoms), and Parkinson's disease. The most advanced program, ALTO-207, is a fixed-dose combination of pramipexole and ondansetron for TRD, acquired from Chase Therapeutics in May 2025, with a Phase 2b/potential pivotal trial expected to start in H1 2026. Other key programs include ALTO-300, a biomarker-selected agomelatine trial in MDD with topline data expected mid-2026, and ALTO-101, a transdermal PDE4 inhibitor for cognitive symptoms of schizophrenia with Phase 2 data expected around Q1 2026. What distinguishes Alto is its "Precision Psychiatry Platform," which uses EEG, neurocognitive assessments, wearables, genetic data, and machine learning to identify biomarkers predicting patient drug response — the goal being cleaner efficacy signals in enriched patient populations. Most of Alto's drug candidates are in-licensed or acquired, meaning future commercial success would trigger royalty payments and milestone obligations to counterparties including Sanofi, Cerecor, and Chase. Alto funds operations through equity raises and non-dilutive sources, including a Wellcome Trust convertible grant supporting ALTO-100. The company has 68 employees, with 54 in R&D.